Fc 및 당쇄 변형 항체 시장 - 엔지니어링 유형별, 치료 유형별, 치료 영역별, 투여 경로별, 주요 지역별: 산업 동향 및 세계 전망

The Fc and glycoengineered antibodies market is valued at USD 38.8 billion in 2024 growing at a CAGR of 5.86% during the forecast period 2024-2035.

Antibody-based pharmacological interventions have emerged as one of the fastest-growing segments within the biopharmaceutical industry, with a staggering number of approved monoclonal antibodies exceeding 120, and nearly 900 registered clinical trials for evaluation. This burgeoning field is projected to contribute significantly to global sales, surpassing USD 300 billion by 2025, underscoring its pivotal role in the healthcare landscape. The therapeutic efficacy of a drug, defined as its ability to produce the desired therapeutic effects in treating a particular disease, is a paramount consideration. A drug with high therapeutic efficacy offers improved treatment outcomes by increasing target specificity, reducing side effects, and extending the drug's half-life. To enhance the therapeutic efficacy of antibodies, various Fc and glycoengineering strategies have been developed recently.

Fc engineering focuses on modifying the Fc regions of antibodies to enhance their effector functions, such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC), thereby increasing the molecule's half-life. Conversely, glycoengineering optimizes the pharmacokinetic and pharmacodynamic properties of therapeutic antibodies by controlling the glycan composition within the molecule. These engineered antibodies are widely utilized in enhancing the anti-tumor potential of monoclonal antibodies. Currently, numerous drug developers and technology providers in this domain are actively engaged in developing various Fc and glycoengineered antibodies. Additionally, several major pharmaceutical companies have demonstrated a keen interest in these engineered antibodies, investing substantial resources in terms of time and capital into the Fc and glycoengineered antibodies market. Presently, over 150 Fc and glycoengineered antibodies have received global approval, with notable recent examples (in 2023) including Retifanlimab, Elranatamab, Glofitamab, and Tislelizumab.

Driven by the promising antibody-based drug pipeline, ongoing technical advancements, and the growing interest of biopharmaceutical developers, the Fc and glycoengineered antibodies market is poised to witness remarkable growth during the forecast period. This burgeoning field holds immense potential for improving therapeutic outcomes and advancing the frontiers of personalized medicine.

Key Market Segments

Type of Engineering

• Fc Engineered Antibodies
• Glycoengineered Antibodies

Type of Therapy

• Monotherapy
• Combination Therapy
• Both

Therapeutic Area

• Autoimmune Disorders
• Dermatological Disorders
• Oncological Disorders
• Rare Diseases
• Other Disorders

Route of Administration

• Intravenous Route
• Subcutaneous Route
• Intramuscular Route

Geographical Regions

• North America
• Europe
• Asia-Pacific
• Rest of the World

Research Coverage:

• The report studies the Fc and glycoengineered antibodies market based on type of engineering, type of therapy, therapeutic area, route of administration, and key geographical regions
• The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.
• The report forecasts the revenue of market segments with respect to five major regions
• A general overview of antibodies, including structure, historical discovery timeline, isotypes, and mechanisms of action. Brief overview of Fc region, effector functions, Fc receptor types, engineering (glycoengineering, protein engineering, isotype chimerism), and future growth perspectives.
• Detailed assessment of over 170 marketed/development antibody programs for various indications. Analysis based on development phase, antibody type, engineering type, impact, target, therapy type, disease indication, therapeutic area, administration route, and popular Fc engineering technologies.
• Elaborate profiles of prominent Fc-engineered antibody developers, including company overview, financials, drug portfolio, recent developments, and future outlook.
• In-depth analysis of completed, ongoing, and planned clinical trials of Fc and glycoengineered antibodies based on trial parameters like registration year, status, phase, patient population, sponsor type, active players, study design, indication, and geography.
• Detailed analysis of partnerships since 2016 based on year, type, engineering type, therapeutic area, active players, and regional distribution.
• Analysis of grants (2019-2024) for Fc/glycoengineered antibody projects based on award year, amount, funding source, period, application type, purpose, activity code, study section, NIH departments, program officers, and recipient organizations.
• Elaborate patent analysis covering types, years, applicant types, geographies, CPC symbols, active players, benchmarking, and valuation of leading patents by citations.
• Detailed 2024-2035 market forecast estimating current size and future opportunity based on engineering types, therapy types, therapeutic areas, administration routes, key regions, and revenues from marketed/phase III drugs.

Key Benefits of Buying this Report

• The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
• Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
• The report provides stakeholders with a pulse on the Fc and glycoengineered antibodies market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Key Market Companies

• AbbVie
• Akesobio
• Alexion Pharmaceuticals
• Amgen
• AstraZeneca
• Boehringer Ingelheim
• Genentech
• MacroGenics
• MorphoSys
• Kyowa Kirin
• Xencor

TABLE OF CONTENTS

1. PREFACE

• 1.1. Introduction
• 1.2. Market Share Insights
• 1.3. Key Market Insights
• 1.4. Report Coverage
• 1.5. Key Questions Answered
• 1.6. Chapter Outlines

2 RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
• 2.3. Project Methodology
• 2.4. Forecast Methodology
• 2.5. Robust Quality Control
• 2.6. Key Considerations
  • 2.6.1. Demographics
  • 2.6.2. Economic Factors
  • 2.6.3. Government Regulations
  • 2.6.4. Supply Chain
  • 2.6.5. COVID Impact / Related Factors
  • 2.6.6. Market Access
  • 2.6.7. Healthcare Policies
  • 2.6.8. Industry Consolidation
• 2.7. Key Market Segmentations

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

• 3.1. Chapter Overview
• 3.2. Market Dynamics
  • 3.2.1. Time Period
    • 3.2.1.1. Historical Trends
    • 3.2.1.2. Current and Forecasted Estimates
  • 3.2.2. Currency Coverage
    • 3.2.2.1. Major Currencies Affecting the Market
    • 3.2.2.2. Impact of Currency Fluctuations on the Industry
    • 3.2.2.3. Foreign Exchange Impact
    • 3.2.2.4. Evaluation of Foreign Exchange Rates and Their Impact on Market
    • 3.2.2.5. Strategies for Mitigating Foreign Exchange Risk
  • 3.2.3. Recession
    • 3.2.3.1. Historical Analysis of Past Recessions and Lessons Learnt
    • 3.2.3.2. Assessment of Current Economic Conditions and Potential Impact on the Market
  • 3.2.4. Inflation
    • 3.4.4.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 3.4.4.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

• 4.1. Chapter Overview

5. INTRODUCTION

• 5.1. Chapter Overview
• 5.2. Structure of Antibodies
• 5.3. Historical Timeline of Antibody Development
• 5.4. Antibody Isotypes
• 5.5. Mechanism of Action of Antibodies
• 5.6. Fc Region and Effector Functions
  • 5.6.1. Types of Fc Receptors
  • 5.6.2. Engineering of the Fc Region
    • 5.6.2.1. Glycoengineering
    • 5.6.2.2. Protein Engineering
    • 5.6.2.3. Isotype Chimerism
• 5.7. Future Perspective

6. MARKET LANDSCAPE

• 6.1. Chapter Overview
• 6.2. Fc Engineered and Glycoengineered Antibodies: Overall Pipeline
  • 6.2.1. Analysis by Stage of Development
  • 6.2.2. Analysis by Type of Antibody
  • 6.2.3. Analysis by Type of Engineering
  • 6.2.4. Analysis by Impact of Engineering
  • 6.2.5. Analysis by Biological Target
  • 6.2.6. Analysis by Type of Therapy
  • 6.2.7. Analysis by Target Disease Indication
  • 6.2.8. Analysis by Therapeutic Area
  • 6.2.9. Analysis by Route of Administration
  • 6.2.10. Popular Fc Engineering Technologies: Analysis by Number of Marketed Drugs and Development Programs
• 6.3. Fc Engineered and Glycoengineered Antibodies: Overall Developer Landscape
  • 6.3.1 Analysis by Year of Establishment
  • 6.3.2 Analysis by Company Size
  • 6.3.3 Analysis by Location of Headquarters
  • 6.3.4. Leading Developers: Analysis by Number of Drugs

7. COMPANY PROFILES

• 7.1. Chapter Overview
• 7.2. Detailed Company Profiles of Leading Fc Engineered and Glycoengineered Antibody Drug Developers
  • 7.2.1. AbbVie
    • 7.2.1.1. Company Overview
    • 7.2.1.2. Financial Information
    • 7.2.1.3. Drug Portfolio
      • 7.2.1.3.1. Drug Profile: Skyrizi
    • 7.2.1.4. Recent Developments and Future Outlook
  • 7.2.2. Alexion Pharmaceuticals
    • 7.2.2.1. Company Overview
    • 7.2.2.2. Drug Portfolio
      • 7.2.2.2.1. Drug Profile: Soliris
      • 7.2.2.2.2. Drug Profile: Ultomiris
    • 7.2.2.3. Recent Developments and Future Outlook
  • 7.2.3. AstraZeneca
    • 7.2.3.1. Company Overview
    • 7.2.3.2. Financial Information
    • 7.2.3.3. Drug Portfolio
      • 7.2.3.3.1. Drug Profile: Beyfortus
      • 7.2.3.3.2. Drug Profile: Imfinzi
      • 7.2.3.3.3. Drug Profile: Fasenra
      • 7.2.3.3.4. Drug Profile: Saphnelo
    • 7.2.3.4. Recent Developments and Future Outlook
  • 7.2.4. Genentech
    • 7.2.4.1. Company Overview
    • 7.2.4.2. Financial Information
    • 7.2.4.3. Drug Portfolio
      • 7.2.4.3.1. Drug Profile: Gazyva
      • 7.2.4.3.2. Drug Profile: Ocrevus
      • 7.2.4.3.3. Drug Profile: Tecentriq
    • 7.2.4.4. Recent Developments and Future Outlook
  • 7.2.5. MacroGenics
    • 7.2.5.1. Company Overview
    • 7.2.5.2. Financial Information
    • 7.2.5.3. Drug Portfolio
      • 7.2.5.3.1. Drug Profile: Margenza
      • 7.2.5.3.2. Drug Profile: MGA-271
    • 7.2.5.4. Recent Developments and Future Outlook
  • 7.2.6. Kyowa Kirin
    • 7.2.6.1. Company Overview
    • 7.2.6.2. Financial Information
    • 7.2.6.3. Drug Portfolio
      • 7.2.6.3.1. Drug Profile: POTELIGEO
    • 7.2.6.4. Recent Developments and Future Outlook
• 7.3. Short Company Profiles of Leading Fc Engineered and Glycoengineered Antibody Drug Developers
  • 7.3.1. Akeso Biopharma
    • 7.3.1.1. Company Overview
    • 7.3.1.2. Drug Portfolio
      • 7.3.1.2.1. Drug Profile: Penpulimab
  • 7.3.2. Amgen
    • 7.3.2.1. Company Overview
    • 7.3.2.2. Drug Portfolio
      • 7.3.2.2.1. Drug Profile: Bemarituzuman
      • 7.3.2.2.2. Drug Profile: STEAP1 XmAb Antibody
      • 7.3.2.2.3. Drug Profile: FPA157
  • 7.3.3. Boehringer Ingelheim
    • 7.3.3.1. Company Overview
    • 7.3.3.2. Drug Portfolio
      • 7.3.3.2.2. Drug Profile: Spesolimab
  • 7.3.4. MorphoSys
    • 7.3.4.1. Company Overview
    • 7.3.4.2. Drug Portfolio
      • 7.3.4.2.1. Drug Portfolio: Tafasitamab
  • 7.3.5. Xemcor
    • 7.3.5.1. Company Overview
    • 7.3.5.2. Drug Portfolio
      • 7.3.5.2.1. Drug Portfolio: Tidutamab
      • 7.3.5.2.2. Drug Portfolio: XmAb22841
      • 7.3.5.2.3. Drug Portfolio: XmAb23104
      • 7.3.5.2.4. Drug Portfolio: Plamotamab
      • 7.3.5.2.5. Drug Portfolio: Vibecotamab
      • 7.3.5.2.6. Drug Portfolio: RO7310729
      • 7.3.5.2.7. Drug Portfolio: XmAb20717
      • 7.3.5.2.8. Drug Portfolio: XmAb819
      • 7.3.5.2.9. Drug Portfolio: XmAb27564
      • 7.3.5.2.10. Drug Portfolio: VRC01LS

8. CLINICAL TRIAL ANALYSIS

• 8.1. Chapter Overview
• 8.2. Scope and Methodology
• 8.3. Fc Engineered and Glycoengineered Antibodies: Clinical Trial Analysis
  • 8.3.1. Analysis by Trial Registration Year
  • 8.3.2. Analysis of Number of Patients Enrolled by Trial Registration Year
  • 8.3.3. Analysis by Trial Phase
  • 8.3.4. Analysis of Number of Patients Enrolled by Trial Phase
  • 8.3.5. Analysis by Trial Registration Year and Trial Phase
  • 8.3.6. Analysis by Trial Status
  • 8.3.7. Analysis by Patient Gender
  • 8.3.8. Analysis by Target Indication
  • 8.3.9. Analysis by Study Design
    • 8.3.9.1. Analysis by Type of Trial Masking
    • 8.3.9.2. Analysis by Type of Intervention Model
    • 8.3.9.3. Analysis by Type of Trial Purpose
    • 8.3.9.4. Analysis by Design Allocation
  • 8.3.10. Most Active Sponsor / Collaborator: Analysis by Number of Registered Trials
    • 8.3.10.1. Analysis by Leading Industry Players
    • 8.3.10.2. Analysis by Leading Non-Industry Players
  • 8.3.11. Analysis by Geography
    • 8.3.11.1. Analysis of Clinical Trials by Trial Status and Geography
    • 8.3.11.2. Analysis of Patients Enrolled by Trial Status and Geography

9. PARTNERSHIPS AND COLLABORATIONS

• 9.1. Chapter Overview
• 9.2. Partnership Models
• 9.3. Fc Engineered and Glycoengineered Antibodies: Partnerships and Collaborations
  • 9.3.1. Analysis by Year of Partnership
  • 9.3.2. Analysis by Type of Partnership
  • 9.3.3. Analysis by Year and Type of Partnership
  • 9.3.4. Analysis by Type of Engineering
  • 9.3.5. Analysis by Therapeutic Area
  • 9.3.6. Most Active Players: Analysis by Number of Partnerships
  • 9.3.7. Analysis by Geography
    • 9.3.7.1. Intracontinental and Intercontinental Agreements
    • 9.3.7.2. Local and International Agreements

10. GRANT ANALYSIS

• 10.1. Chapter Overview
• 10.2. Scope and Methodology
• 10.3. Fc Engineered and Glycoengineered Antibodies: Grant Analysis
  • 10.3.1. Analysis by Year of Grant Award
  • 10.3.2. Analysis by Amount Awarded
  • 10.3.3. Analysis by Funding Institute Center
  • 10.3.4. Analysis by Support Period
  • 10.3.5. Analysis by Funding Institute Center and Support Period
  • 10.3.6. Analysis by Type of Grant Application
  • 10.3.7. Analysis by Purpose of Grant Award
  • 10.3.8. Analysis by Activity Code
  • 10.3.9. Analysis by Study Section Involved
  • 10.3.10. Most Popular NIH Departments: Analysis by Number of Grants
    • 10.3.10.1. Prominent Program Officers: Analysis By Number of Grants
    • 10.3.10.2. Popular Recipient Organizations: Analysis by Number of Grants
    • 10.3.10.3. Popular Recipient Organizations: Analysis by Grant Amount
  • 10.3.11. Popular Recipient Organizations: Distribution by States in the US

11. PATENT ANALYSIS

• 11.1. Chapter Overview
• 11.2. Scope and Methodology
• 11.3. Fc Engineered and Glycoengineered Antibodies: Patent Analysis
  • 11.3.1. Analysis by Patent Publication Year
  • 11.3.2. Analysis by Patent Application Year
  • 11.3.3. Analysis by Granted Patents and Patent Applications, 2019-2023
  • 11.3.4. Analysis by Patent Jurisdiction
  • 11.3.5. Analysis by CPC Symbols
  • 11.3.6. Analysis by Type of Applicant
  • 11.3.7. Leading Industry Players: Analysis by Number of Patents
  • 11.3.8. Leading Non-Industry Players: Analysis by Number of Patents
  • 11.3.9. Leading Patent Assignees: Analysis by Number of Patents
  • 11.3.10. Patent Benchmarking Analysis
    • 11.3.10.1. Analysis by Patent Characteristics
  • 11.3.11. Patent Valuation
  • 11.3.12. Leading Patents by Number of Citations

12. GLOBAL Fc ENGINEERED AND GLYCOENGINEERED ANTIBODIES MARKET

• 12.1. Chapter Overview
• 12.2. Key Assumptions and Methodology
• 12.3. Global Fc Engineered and Glycoengineered Antibodies Market, Historical Trends (2019-2023) and Future Estimates (2024-2035)
  • 12.3.1. Scenario Analysis
    • 12.3.1.1. Conservative Scenario
    • 12.3.1.2. Optimistic Scenario
• 12.4. Key Market Segmentations

13. Fc ENGINEERED AND GLYCOENGINEERED ANTIBODIES MARKET, BY TYPE OF ENGINEERING

• 13.1. Chapter Overview
• 13.2. Key Assumptions and Methodology
• 13.3. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Type of Engineering, 2024 and 2035
  • 13.3.1. Fc Engineered Antibodies Market, 2024-2035
  • 13.3.2. Glycoengineered Antibodies Market, 2024-2035
• 13.4. Data Triangulation and Validation

14. Fc ENGINEERED AND GLYCOENGINEERED ANTIBODIES MARKET, BY TYPE OF THERAPY

• 14.1. Chapter Overview
• 14.2. Key Assumptions and Methodology
• 14.3. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Type of Therapy, 2024 and 2035
  • 14.3.1. Fc Engineered and Glycoengineered Market for Monotherapy, 2024-2035
  • 14.3.2. Fc Engineered and Glycoengineered Market for Combination Therapy, 2024-2035
  • 14.3.3. Fc Engineered and Glycoengineered Market for Both, 2024-2035
• 14.4. Data Triangulation and Validation

15. Fc ENGINEERED AND GLYCOENGINEERED ANTIBODIES MARKET, BY THERAPEUTIC AREA

• 15.1. Chapter Overview
• 15.2. Key Assumptions and Methodology
• 15.3. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Therapeutic Area, 2024 and 2035
  • 15.3.1. Fc Engineered and Glycoengineered Market for Oncological Disorders, 2024-2035
  • 15.3.2. Fc Engineered and Glycoengineered Market for Dermatological Disorders, 2024-2035
  • 15.3.3. Fc Engineered and Glycoengineered Market for Autoimmune Disorders, 2024-2035
  • 15.3.4. Fc Engineered and Glycoengineered Market for Rare Disorders, 2024-2035
  • 15.3.4. Fc Engineered and Glycoengineered Market for Other Disorders, 2024-2035
• 15.4. Data Triangulation and Validation

16. Fc ENGINEERED AND GLYCOENGINEERED ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION

• 16.1. Chapter Overview
• 16.2. Key Assumptions and Methodology
• 16.3. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Route of Administration, 2024 and 2035
  • 16.3.1. Fc Engineered and Glycoengineered Market for Intravenous Route, 2024-2035
  • 16.3.2. Fc Engineered and Glycoengineered Market for Subcutaneous Route, 2024-2035
  • 16.3.3. Fc Engineered and Glycoengineered Market for Intramuscular Route, 2024-2035
• 16.4. Data Triangulation and Validation

17. Fc ENGINEERED AND GLYCOENGINEERED ANTIBODIES MARKET, BY KEY GEOGRAPHICAL REGIONS

• 17.1. Chapter Overview
• 17.2. Key Assumptions and Methodology
• 17.3. Fc Engineered and Glycoengineered Antibodies Market: Distribution by Key Geographical Regions, 2024 and 2035
  • 17.3.1. Fc Engineered and Glycoengineered Market in North America, 2024-2035
  • 17.3.2. Fc Engineered and Glycoengineered Market in Europe, 2024-2035
  • 17.3.3. Fc Engineered and Glycoengineered Market in Asia-Pacific, 2024-2035
  • 17.3.4. Fc Engineered and Glycoengineered Market in Rest of the World, 2024-2035
• 17.4. Data Triangulation and Validation

18. Fc ENGINEEREDAND GLYCOENGINEERED ANTIBODIES MARKET,SALES FORECAST OF DRUGS

• 18.1. Chapter Overview
• 18.2. Key Assumptions and Methodology
• 18.3. Commercialized Fc Engineered and Glycoengineered Antibodies Market: Sales Forecast
  • 18.3.1. AK-105 Sales Forecast
  • 18.3.2. BeyfortusTM Sales Forecast
  • 18.3.3. Briumvi(R) Sales Forecast
  • 18.3.4. Fasenra(R) Sales Forecast
  • 18.3.5. Gazyva(R) Sales Forecast
  • 18.3.6. Imfinzi(R) Sales Forecast
  • 18.3.7. Margenza Sales Forecast
  • 18.3.8. Monjuvi(R) Sales Forecast
  • 18.3.9. Ocrevus(R) Sales Forecast
  • 18.3.10. POTELIGEO(R) Sales Forecast
  • 18.3.11. Saphnelo(R) Sales Forecast
  • 18.3.12. Skyrizi(R) Sales Forecast
  • 18.3.13. Soliris(R) Sales Forecast
  • 18.3.14. Tecentriq(R) Sales Forecast
  • 18.3.15. Tislelizumab Sales Forecast
  • 18.3.16. Tzield(R) Sales Forecast
  • 18.3.17. Ultomiris(R) Sales Forecast
  • 18.3.18. Uplizna(R) Sales Forecast
• 18.4. Phase III Fc Engineered and Glycoengineered Antibodies Market: Sales Forecast
  • 18.4.1. Clazakizumab Sales Forecast
  • 18.4.2. FPA144 Sales Forecast
  • 18.4.3. Skyrizi Sales Forecast
  • 18.4.4. TQ-B2450 Sales Forecast
  • 18.4.5. Visterra Sales Forecast
• 18.6. Data Triangulation and Validation

19. CONCLUDING REMARKS

• 19.1. Chapter Overview

20 APPENDIX I: TABULATED DATA

21 APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS